Comparative efficacy and safety of cabozantinib for malignant tumors: a systematic review and meta-analysis

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca A Cancer J Clinicians. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. Ca A Cancer J Clinicians. 2024;74(1):12–49. doi: 10.3322/caac.21820
   PubMed Web of Science ®Google Scholar
• Osanto S, van der Hulle T. Cabozantinib in the treatment of advanced renal cell carcinoma in adults following prior vascular endothelial growth factor targeted therapy: clinical trial evidence and experience. Ther Adv Urol. 2018;10(3):109–123. doi: 10.1177/1756287217748867
   PubMed Web of Science ®Google Scholar
• de Bono JS, Yap TA. C-MET: an exciting new target for anticancer therapy. Therapeut Adv Med Oncol. 2011;3(1 Suppl):S3–5. doi: 10.1177/1758834011423402
   PubMedGoogle Scholar
• Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103. doi: 10.1038/nrc3205
   PubMed Web of Science ®Google Scholar
• Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia (New York, NY). 2010;12(1):1–10. doi: 10.1593/neo.09948
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature. 2011;473(7347):298–307. doi: 10.1038/nature10144
   PubMed Web of Science ®Google Scholar
• Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer. 2009;100(1):1–7. doi: 10.1038/sj.bjc.6604767
   PubMed Web of Science ®Google Scholar
• Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–231. doi: 10.1016/j.ccr.2009.01.027
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308. doi: 10.1158/1535-7163.Mct-11-0264
   PubMed Web of Science ®Google Scholar
• Cabozantinib. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
   Google Scholar
• Xu J, Higgins MJ, Tolaney SM, et al. A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases [article]. Oncology. 2020;25(8):652–660. doi: 10.1634/theoncologist.2020-0127
   Google Scholar
• Vergote IB, Smith DC, Berger R, et al. A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma [article]. Eur J Cancer. 2017;83:229–236. doi: 10.1016/j.ejca.2017.06.018
   PubMed Web of Science ®Google Scholar
• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial [article]. J Clin Oncol. 2013;31(4):412–419. doi: 10.1200/JCO.2012.45.0494
   PubMed Web of Science ®Google Scholar
• Smith MR, Sweeney CJ, Corn PG, et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study [article]. J Clin Oncol. 2014;32(30):3391–3399. doi: 10.1200/JCO.2013.54.5954
   PubMed Web of Science ®Google Scholar
• Daud A, Kluger HM, Kurzrock R, et al. Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma [article]. Br j cancer. 2017;116(4):432–440. doi: 10.1038/bjc.2016.419
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Elisei R, Müller S, et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma [article]. Ann Oncol. 2017;28(11):2813–2819. doi: 10.1093/annonc/mdx479
   PubMed Web of Science ®Google Scholar
• Schöffski P, Gordon M, Smith DC, et al. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours [article]. Eur J Cancer. 2017;86:296–304. doi: 10.1016/j.ejca.2017.09.011
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma [article]. N Engl J Med. 2018;379(1):54–63. doi: 10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Brose MS, Robinson BG, Sherman SI, et al. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial [article]. Cancer. 2022;128(24):4203–4212. doi: 10.1002/cncr.34493
   PubMed Web of Science ®Google Scholar
• Su J, Lu J, Zhang J, et al. A meta-analysis of the efficacy and toxicity of tyrosine kinase inhibitors in treating patients with different types of thyroid cancer: how to choose drugs appropriately? Curr Opin Oncol. 2023;35(2):132–144. doi: 10.1097/cco.0000000000000924
   PubMed Web of Science ®Google Scholar
• Su J, Wang M, Fu Y, et al. Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials. Expert Rev Anticancer Ther. 2022;22(9):999–1008. doi: 10.1080/14737140.2022.2102000
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Di Bari F, et al. Cabozantinib in thyroid cancer. Recent Pat Anticancer Drug Discov. 2015;10(3):259–269. doi: 10.2174/1574892810666150708110816
   PubMed Web of Science ®Google Scholar
• Duke ES, Barone AK, Chatterjee S, et al. FDA approval summary: cabozantinib for differentiated thyroid cancer. Clin Cancer Res. 2022;28(19):4173–4177. doi: 10.1158/1078-0432.Ccr-22-0873
   PubMed Web of Science ®Google Scholar
• Shiozawa Y, Pedersen EA, Patel LR, et al. GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia (New York, NY). 2010;12(2):116–127. doi: 10.1593/neo.91384
   PubMed Web of Science ®Google Scholar
• Paccez JD, Vasques GJ, Correa RG, et al. The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target. Oncogene. 2013;32(6):689–698. doi: 10.1038/onc.2012.89
   PubMed Web of Science ®Google Scholar
• Mishra A, Wang J, Shiozawa Y, et al. Hypoxia stabilizes GAS6/Axl signaling in metastatic prostate cancer. Mol Cancer Res. 2012;10(6):703–712. doi: 10.1158/1541-7786.Mcr-11-0569
   PubMed Web of Science ®Google Scholar
• Wu YM, Robinson DR, Kung HJ. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res. 2004;64(20):7311–7320. doi: 10.1158/0008-5472.Can-04-0972
   PubMed Web of Science ®Google Scholar
• Smith M, De Bono J, Sternberg C, et al. Phase III study of cabozantinib in Previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34(25):3005–3013. doi: 10.1200/jco.2015.65.5597
   PubMed Web of Science ®Google Scholar
• Agarwal N, Azad A, Carles J, et al. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022;18(10):1185–1198. doi: 10.2217/fon-2021-1096
   PubMed Web of Science ®Google Scholar
• Scheiner B, Kirstein MM, Hucke F, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther. 2019;49(10):1323–1333. doi: 10.1111/apt.15245
   PubMed Web of Science ®Google Scholar
• Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(8):995–1008. doi: 10.1016/s1470-2045(22)00326-6
   PubMed Web of Science ®Google Scholar
• Huang A, Yang XR, Chung WY, et al. Targeted therapy for hepatocellular carcinoma. Signal transduction and targeted therapy. Signal Transduct Target Ther. 2020;5(1):146. doi: 10.1038/s41392-020-00264-x
   PubMed Web of Science ®Google Scholar
• Pinato DJ, Fessas P, Cortellini A, et al. Combined PD-1/VEGFR blockade: a new era of treatment for hepatocellular cancer [review]. Clin Cancer Res. 2021;27(4):908–910. doi: 10.1158/1078-0432.CCR-20-4069
   PubMed Web of Science ®Google Scholar
• Liu Z, Lin Y, Zhang J, et al. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exper Cli Can Res CR. 2019;38(1):447. doi: 10.1186/s13046-019-1412-8
   PubMed Web of Science ®Google Scholar
• Shigeta K, Datta M, Hato T, et al. Dual programmed death receptor-1 and vascular endothelial growth factor receptor-2 blockade promotes vascular normalization and enhances antitumor immune responses in hepatocellular carcinoma. Hepatology. 2020;71(4):1247–1261. doi: 10.1002/hep.30889
   PubMed Web of Science ®Google Scholar
• Xing R, Gao J, Cui Q, et al. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol. 2021;12:783236. doi: 10.3389/fimmu.2021.783236
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646. doi: 10.1200/jco.2012.48.4659
   PubMed Web of Science ®Google Scholar
• Li J, Gu J. Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2017;73(10):1209–1217. doi: 10.1007/s00228-017-2299-y
   PubMed Web of Science ®Google Scholar
• Milling RV, Grimm D, Krüger M, et al. Pazopanib, cabozantinib, and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension. Int J Mol Sci. 2018;19(10):3258. doi: 10.3390/ijms19103258
   PubMed Web of Science ®Google Scholar
• Facemire CS, Nixon AB, Griffiths R, et al. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54(3):652–658. doi: 10.1161/hypertensionaha.109.129973
   PubMed Web of Science ®Google Scholar
• Kruzliak P, Kovacova G, Pechanova O. Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension. Angiogenesis. 2013;16(2):289–295. doi: 10.1007/s10456-012-9327-4
   PubMed Web of Science ®Google Scholar
• Dirix LY, Maes H, Sweldens C. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann Oncol. 2007;18(6):1121–1122. doi: 10.1093/annonc/mdm205
   PubMed Web of Science ®Google Scholar
• Bamias A, Manios E, Karadimou A, et al. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. Eur J Cancer. 2011;47(11):1660–1668. doi: 10.1016/j.ejca.2011.03.033
   PubMed Web of Science ®Google Scholar
• Procopio G, Claps M, Pircher C, et al. A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: the BREAKPOINT trial (Meet-Uro trial 03). Tumori. 2023;109(1):129–137. doi: 10.1177/03008916221138881
   PubMed Web of Science ®Google Scholar
• Procopio G, Sepe P, Claps M, et al. Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma: results of the BONSAI trial for the Italian Network for Research in urologic-oncology (meet-URO 2 study). JAMA Oncol. 2022;8(6):910–913. doi: 10.1001/jamaoncol.2022.0238
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Pal SK, McDermott DF, et al. A phase I study of cabozantinib (XL184) in patients with renal cell cancer [article]. Ann Oncol. 2014;25(8):1603–1608. doi: 10.1093/annonc/mdu184
   PubMed Web of Science ®Google Scholar
• Bodnar L, Kopczyńska A, Żołnierek J, et al. Real-world experience of Cabozantinib as second- or subsequent line treatment in patients with metastatic renal cell carcinoma: data from the Polish managed access program [article]. Clin Genitourin Cancer. 2019;17(3):e556–e564. doi: 10.1016/j.clgc.2019.02.002
   PubMed Web of Science ®Google Scholar
• Tomita Y, Tatsugami K, Nakaigawa N, et al. Cabozantinib in advanced renal cell carcinoma: a phase II, open-label, single-arm study of Japanese patients. Int J Urol. 2020;27(11):952–959. doi: 10.1111/iju.14329
   PubMed Web of Science ®Google Scholar
• O’Sullivan CG, Kummar S, Hu J, et al. Clinical activity of single-agent cabozantinib (XL184), a multi-receptor Tyrosine Kinase Inhibitor, in patients with refractory soft-tissue sarcomas [article]. Clinical Cancer Research. 2022;28(2):279–288. doi: 10.1158/1078-0432.CCR-21-2480
   PubMed Web of Science ®Google Scholar